We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Akero Therapeutics Inc
11 own
7 watching
Current Price
$26.41
$0.06
(0.23%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,822.38M
52-Week High
53.77000
52-Week Low
11.25000
Average Volume
0.45M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,822.38M52-Week High53.7700052-Week Low11.25000Average Volume0.45MDividend Yield--P/E Ratio--What does the Akero Therapeutics Inc do?
Akero Therapeutics, Inc. are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Their initial focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Their lead product candidate, AKR-001, which they are developing as a potential treatment for patients with NASH, is an analog of fibroblast growth factor 21, or FGF21. FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body. FGF21 also plays a critical role in protecting many types of cells from various forms of stress. FGF21 agonists have shown evidence of therapeutic benefit in clinical trials of patients with NASH, many of whom are dyslipidemic and insulin resistant. In previous clinical trials in patients with type 2 diabetes, or T2D, administration of AKR-001 was associated with a substantial improvement in lipid metabolism and insulin sensitivity. They believe these data demonstrate AKR-001's potential to serve as a cornerstone for the treatment of NASH. They plan to initiate a Phase 2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019. Akero Therapeutics, Inc. were incorporated in January 2017 under the laws of the State of Delaware under the name Pippin Pharmaceuticals, Inc. On May 16, 2018, they changed their name to Akero Therapeutics, Inc. Their principal executive offices are located at 170Harbor Way, 3rd Floor, South San Francisco, CA 94080.
Read More
How much money does Akero Therapeutics Inc make?
News & Events about Akero Therapeutics Inc.
Globe Newswire
1 year ago
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responsesSOUTH SAN FRANCISCO, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the ...
Globe Newswire
1 year ago
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics,Inc.(Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the...
Frequently Asked Questions
Frequently Asked Questions
What is Akero Therapeutics Inc share price today?
Can Indians buy Akero Therapeutics Inc shares?
How can I buy Akero Therapeutics Inc shares from India?
Can Fractional shares of Akero Therapeutics Inc be purchased?
What are the documents required to start investing in Akero Therapeutics Inc stocks?
What is today’s traded volume of Akero Therapeutics Inc?
What is today’s market capitalisation of Akero Therapeutics Inc?
What is the 52-Week High and Low Range of Akero Therapeutics Inc?
What percentage is Akero Therapeutics Inc down from its 52-Week High?
What percentage is Akero Therapeutics Inc up from its 52-Week Low?
Current Price
$26.41
$0.06
(0.23%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.